Search

Your search keyword '"de Mestier, Louis"' showing total 309 results
Start Over Author "de Mestier, Louis" Language english
309 results on '"de Mestier, Louis"'

3. Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma

Author

Jiang, Lingxi, Qin, Jiejie, Dai, Yuting, Zhao, Shulin, Zhan, Qian, Cui, Peng, Ren, Lingjie, Wang, Xuelong, Zhang, Ruihong, Gao, Chenxu, Zhou, Yanting, Cai, Shangli, Wang, Guoqiang, Xie, Wenchuan, Tang, Xiaomei, Shi, Minmin, Ma, Fangfang, Liu, Jia, Wang, Ting, Wang, Chaofu, Svrcek, Magali, Bardier-Dupas, Armelle, Emile, Jean Francois, de Mestier, Louis, Bachet, Jean-Baptiste, Nicolle, Remy, Cros, Jerome, Laurent-Puig, Pierre, Wei, Miaoyan, Song, Bin, Jing, Wei, Guo, Shiwei, Zheng, Kailian, Jiang, Hui, Wang, Huan, Deng, Xiaxing, Chen, Hao, Tian, Qiang, Wang, Shengyue, Shi, Si, Jin, Gang, Yin, Tong, Fang, Hai, Chen, Saijuan, and Shen, Baiyong

Published
2024
Full Text
View/download PDF

5. Olaparib as maintenance therapy in non resectable pancreatic adenocarcinoma associated with homologous recombination deficiency profile: A French retrospective multicentric AGEO real-world study

Author

M’Baloula, Jeannie, Tougeron, David, Boilève, Alice, Jeanbert, Elodie, Guimbaud, Rosine, Ben Abdelghani, Meher, Durand, Alice, Turpin, Anthony, Quesada, Stanislas, Blanc, Jean Frédéric, Artru, Pascal, Toullec, Clémence, Trouilloud, Isabelle, Pellat, Anna, Touchefeu, Yann, Pinot, Julien, Caroli-Bosc, François-Xavier, Taïeb, Julien, Doat, Solène, Bouché, Olivier, Védie, Anne Laure, de Mestier, Louis, and Muller, Marie

Published
2024
Full Text
View/download PDF

6. Pacpaint: a histology-based deep learning model uncovers the extensive intratumor molecular heterogeneity of pancreatic adenocarcinoma

Author

Saillard, Charlie, Delecourt, Flore, Schmauch, Benoit, Moindrot, Olivier, Svrcek, Magali, Bardier-Dupas, Armelle, Emile, Jean Francois, Ayadi, Mira, Rebours, Vinciane, de Mestier, Louis, Hammel, Pascal, Neuzillet, Cindy, Bachet, Jean Baptiste, Iovanna, Juan, Dusetti, Nelson, Blum, Yuna, Richard, Magali, Kermezli, Yasmina, Paradis, Valerie, Zaslavskiy, Mikhail, Courtiol, Pierre, Kamoun, Aurelie, Nicolle, Remy, and Cros, Jerome

Published
2023
Full Text
View/download PDF

8. French guidelines from the GTE, AFCE and ENDOCAN-RENATEN (Groupe d’étude des Tumeurs Endocrines/Association Francophone de Chirurgie Endocrinienne/Reseau national de prise en charge des tumeurs endocrines) for the screening, diagnosis and management of Multiple Endocrine Neoplasia Type 1

Author

Goudet, Pierre, Cadiot, Guillaume, Barlier, Anne, Baudin, Eric, Borson-Chazot, Françoise, Brunaud, Laurent, Caiazzo, Robert, Cardot-Bauters, Catherine, Castinetti, Frédéric, Chanson, Philippe, Cuny, Thomas, Dansin, Eric, Gaujoux, Sébastien, Giraud, Sophie, Groussin, Lionel, Le Bras, Maëlle, Lifante, Jean-Christophe, Mathonnet, Muriel, de Mestier, Louis, Mirallié, Eric, Pattou, François, Romanet, Pauline, Sebag, Frédéric, Tresallet, Christophe, Vezzosi, Delphine, Walter, Thomas, and Tabarin, Antoine

Published
2024
Full Text
View/download PDF

10. Classification of PRSS1 variants responsible for chronic pancreatitis: An expert perspective from the Franco-Chinese GREPAN Study Group

Author

Abrantes, Amandine, Aguilera Munoz, Lina, Albouys, Jérémie, Alric, Laurent, Amiot, Xavier, Archambeaud, Isabelle, Audiau, Solène, Bastide, Laetitia, Baudon, Julien, Bellaiche, Guy, Bellon, Serge, Bertrand, Valérie, Bideau, Karine, Billiemaz, Kareen, Billioud, Claire, Bonnefoy, Sabine, Borderon, Corinne, Bournet, Barbara, Breton, Estelle, Brugel, Mathias, Buscail, Louis, Cadiot, Guillaume, Camus, Marine, Causse, Xavier, Chamouard, Patrick, Chaput, Ulriikka, Cholet, Franck, Ciocan, Dragos Marius, Clavel, Christine, Coffin, Benoit, Coimet-Berger, Laura, Creveaux, Isabelle, Culetto, Adrian, Daboussi, Oussama, De Mestier, Louis, Degand, Thibault, D'Engremont, Christelle, Denis, Bernard, Dermine, Solène, Desgrippes, Romain, Drouet D'Aubigny, Augustin, Enaud, Raphaël, Fabre, Alexandre, Gargot, Dany, Gelsi, Eve, Gentilcore, Elena, Gincul, Rodica, Ginglinger-Favre, Emmanuelle, Giovannini, Marc, Gomercic, Cécile, Gondran, Hannah, Grainville, Thomas, Grandval, Philippe, Grasset, Denis, Grimaldi, Stéphane, Grimbert, Sylvie, Hagege, Hervé, Heissat, Sophie, Hentic, Olivia, Herber-Mayne, Anne, Hervouet, Marc, Hoibian, Solene, Jacques, Jérémie, Jais, Bénédicte, Kaassis, Mehdi, Koch, Stéphane, Lacaze, Elodie, Lacroute, Joël, Lamireau, Thierry, Laurent, Lucie, Le Guillou, Xavier, Le Rhun, Marc, Leblanc, Sarah, Levy, Philippe, Lievre, Astrid, Lorenzo, Diane, Maire, Frédérique, Marcel, Kévin, Matias, Clément, Mauillon, Jacques, Morgant, Stéphanie, Moussata, Driffa, Muller, Nelly, Nambot, Sophie, Napoleon, Bertrand, Olivier, Anne, Pagenault, Maël, Pelletier, Anne-laure, Pennec, Olivier, Pinard, Fabien, Pioche, Mathieu, Prost, Bénédicte, Queneherve, Lucille, Rebours, Vinciane, Reboux, Noemi, Rekik, Samia, Riachi, Ghassan, Rohmer, Barbara, Roquelaure, Bertrand, Rosa Hezode, Isabelle, Rostain, Florian, Saurin, Jean-Christophe, Servais, Laure, Stan-Iuga, Roxana, Subtil, Clément, Texier, Charles, Thomassin, Lucie, Tougeron, David, Tsakiris, Laurent, Valats, Jean-Christophe, Vuitton, Lucine, Wallenhorst, Timothée, Wangerme, Marc, Zanaldi, Hélène, Zerbib, Frank, Bai, Chen-Guang, Bian, Yun, Cai, Zhen-Zhai, Chang, Xiao-Yan, Chen, Guo-Dong, Cheng, Li, Chen, Yu, Guo, Jin-Tao, Guo, Tao, Han, Jun-Ling, He, Chao-Hui, Hu, Liang-Hao, Huang, Hao-Jie, Huang, Li, Huang, Li-Ya, Huang, Si-Lin, Huang, Wei, Jiang, Fei, Jiang, Hui, Lu, Feng-Chun, Lu, Guo-Tao, Lu, Zi-Peng, Li, Hui-Ping, Li, Jing, Li, Le, Li, Qiang, Li, Xiao-Yu, Lin, Qing, Lin, Yu-Li, Liu, Gai-Fang, Liu, Jie-Min, Liu, Li-Xin, Liu, Pi, Liu, Yi-Pin, Lu, Dong, Shao, Xiao-Dong, Shao, Zhuo, Song, Xu-Rui, Wang, Lei, Wang, Li-Juan, Wang, Li-Sheng, Wang, Lin, Wang, Wei, Wang, Zheng, Wen, Li, Wu, Xi, Xin, Lei, Xue, Jing, Yang, Hong, Yang, Jian-Feng, Yin, Tao, Zhang, Bei-Ping, Zhang, Guo-Wei, Zhang, Hong, Zhang, Rong-Chun, Zhao, Yi-Jun, Zhou, Si-Si, Zhu, Ke-Xiang, Masson, Emmanuelle, Zou, Wen-Bin, Pu, Na, Génin, Emmanuelle, Wu, Hao, Lin, Jin-Huan, Wang, Yuan-Chen, Li, Zhao-Shen, Cooper, David N., Férec, Claude, Liao, Zhuan, and Chen, Jian-Min

Published
2023
Full Text
View/download PDF

21. Outcome on Mesenteric Mass Response of Small-Intestinal Neuroendocrine Tumors Treated by 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: The MesenLuth Study, a National Study from the French Group of Endocrine Tumors and Endocan-RENATEN Network

Author

Al Mansour, Laure, De Mestier, Louis, Haissaguerre, Magalie, Afchain, Pauline, Hadoux, Julien, Lecomte, Thierry, Morland, David, Cottereau, Anne Segolene, De Rycke, Ophelie, Tlili, Ghoufrane, Tordo, Jérémie, Janier, Marc, Deville, Agathe, and Walter, Thomas

Published
2024
Full Text
View/download PDF

22. Digestive Neuroendocrine Neoplasms (NEN): French Intergroup clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, GTE, RENATEN, TENPATH, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, SFR)

Author

de Mestier, Louis, Lepage, Come, Baudin, Eric, Coriat, Romain, Courbon, Frédéric, Couvelard, Anne, Do Cao, Christine, Frampas, Eric, Gaujoux, Sébastien, Gincul, Rodica, Goudet, Pierre, Lombard-Bohas, Catherine, Poncet, Gilles, Smith, Denis, Ruszniewski, Philippe, Lecomte, Thierry, Bouché, Olivier, Walter, Thomas, and Cadiot, Guillaume

Published
2020
Full Text
View/download PDF

29. Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC)

Author

Neuzillet, Cindy, Gaujoux, Sébastien, Williet, Nicolas, Bachet, Jean-Baptiste, Bauguion, Lucile, Colson Durand, Laurianne, Conroy, Thierry, Dahan, Laetitia, Gilabert, Marine, Huguet, Florence, Marthey, Lysiane, Meilleroux, Julie, de Mestier, Louis, Napoléon, Bertrand, Portales, Fabienne, Sa Cunha, Antonio, Schwarz, Lilian, Taieb, Julien, Chibaudel, Benoist, Bouché, Olivier, and Hammel, Pascal

Published
2018
Full Text
View/download PDF

30. Systematic Resection of the Visible Scar After Incomplete Endoscopic Resection of Rectal Neuroendocrine Tumors.

Author

Cheminel, Loïc, Lupu, Alexandru, Wallenhorst, Timothée, Lepilliez, Vincent, Leblanc, Sarah, Albouys, Jérémie, Ali, Einas Abou, Barret, Maximilien, Lorenzo, Diane, De Mestier, Louis, Burtin, Pascal, Girot, Paul, Yann Le Baleur, Gerard, Romain, Yzet, Clara, Tchirikhtchian, Karl, Degand, Thibault, Culetto, Adrian, Lemmers, Arnaud, and Schaefer, Marion

Published
2024
Full Text
View/download PDF

31. Management and outcomes of carcinoid heart disease with liver metastases of midgut neuroendocrine tumours.

Author

Suc, Gaspard, Cachier, Agnès, Hentic, Olivia, Bazire, Baptiste, Sannier, Aurélie, Delhomme, Clémence, Nataf, Patrick, Laschet, Jamila, Deschamps, Lydia, Garbarz, Eric, Ou, Phalla, Caligiuri, Giuseppina, Iung, Bernard, Ruszniewski, Philippe, de Mestier, Louis, and Arangalage, Dimitri

Subjects
VENTRICULAR ejection fraction, TRICUSPID valve diseases, HEART failure, HEART diseases, TRICUSPID valve surgery, NEUROENDOCRINE tumors, CARCINOID, LIVER diseases
Published
2024
Full Text
View/download PDF

32. Characteristics and treatment options of glucagonomas: a national study from the French Group of Endocrine Tumors and ENDOCAN-RENATEN network.

Author

Perrier, Marine, Brugel, Mathias, Gérard, Laura, Goichot, Bernard, Lièvre, Astrid, Lepage, Come, Hautefeuille, Vincent, Do Cao, Christine, Smith, Denis, Thuillier, Philippe, Cros, Jérôme, Cadiot, Guillaume, Walter, Thomas, and de Mestier, Louis

Subjects
GLUCAGONOMA, NEUROENDOCRINE tumors, ANTINEOPLASTIC agents
Abstract

Objective: Glucagonoma is a very rare functional pancreatic neuroendocrine tumor (PanNET). We aimed to provide data on the diagnosis, prognosis, and management of patients with glucagonoma. Design and Methods: In this retrospective national cohort, we included all patients with glucagonoma, defined by at least 1 major criterion (necrolytic migratory erythema [NME] and/or recent-onset diabetes, and/or weight loss ≥ 5 kg) associated with either glucagonemia > 2 x upper limit of normal or positive glucagon immunostaining. Antisecretory efficacy was defined as partial/complete resolution of glucagonoma symptoms. Antitumor efficacy was assessed according to the time to next treatment (TTNT). Results: Thirty-eight patients were included with median age 58.7 yo, primary PanNET located in the tail (68.4%), synchronous metastases (63.2%). Median Ki-67 index was 3%. Most frequent glucagonoma symptoms at diagnosis were NME (86.8%), weight loss (68.4%), and diabetes (50%). Surgery of the primary PanNET was performed in 76.3% of cases, mainly with curative intent (61.5%). After surgery, complete resolution of NME was seen in 93.8% (n = 15/16). The secretory response rates were 85.7%, 85.7%, 75%, and 60% with surgery of metastases (n = 6/7), chemotherapy (n = 6/7), liver-directed therapy (n = 6/8), and somatostatin analogs (n = 6/10), respectively. All lines combined, longer TTNT was reported with chemotherapy (20.2 months). Median overall survival (OS) was 17.3 years. The Ki-67 index > 3% was associated with shorter OS (hazard ratio 5.27, 95% CI [1.11-24.96], P = .036). Conclusion: Patients with glucagonoma had prolonged survival, even in the presence of metastases at diagnosis. Curative-intent surgery should always be considered. Chemotherapy, peptide receptor radionuclide therapy, or liver-directed therapy seems to provide both substantial antitumor and antisecretory efficacies. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

33. European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours.

Author

Kos‐Kudła, Beata, Castaño, Justo P., Denecke, Timm, Grande, Enrique, Kjaer, Andreas, Koumarianou, Anna, de Mestier, Louis, Partelli, Stefano, Perren, Aurel, Stättner, Stefan, Valle, Juan W., and Fazio, Nicola

Subjects
NEUROENDOCRINE tumors, PROGNOSIS, THERAPEUTICS
Abstract

This ENETS guidance paper for well‐differentiated nonfunctioning pancreatic neuroendocrine tumours (NF‐Pan‐NET) has been developed by a multidisciplinary working group, and provides up‐to‐date and practical advice on the management of these tumours. Using the extensive experience of centres treating patients with NF‐Pan‐NEN, the authors of this guidance paper discuss 10 troublesome questions in everyday clinical practice. Our many years of experience in this field are still being verified in the light of the results of new clinical, which set new ways of proceeding in NEN. The treatment of NF‐Pan‐NEN still requires a decision of a multidisciplinary team of specialists in the field of neuroendocrine neoplasms. This ENETS guidance paper provides up‐to‐date practical advice on the NF‐Pan‐NET diagnosis and treatment. Management of NF‐Pan‐NET patients requires a NET‐dedicated MDT decision. ENETS Centres of Excellence should be strongly considered to be involved in the diagnostic‐therapeutic strategy of these patients. Further studies are needed to fulfil the unmet needs in this field focusing on prognostic molecular markers, dilemmas concerning the selection of a therapeutic approach as well as the sequence of their use to achieve success in the management of NF‐Pan‐NETs patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

39. High Tumor Uptake on 18F-FDOPA PET/CT Indicates Poor Prognosis in Patients with Metastatic Midgut Neuroendocrine Tumors: A Study from the Groupe d'étude des Tumeurs Endocrines and ENDOCAN-RENATEN Network.

Author

De Rycke, Ophélie, Perrier, Marine, Ouvrard, Éric, Mennetrey, Clément, Lachachi, Choaib, Bando-Delaunay, Aurélie, Morland, David, Goichot, Bernard, Taieb, David, Walter, Thomas, Cadiot, Guillaume, Cros, Jérôme, Hentic, Olivia, Ruszniewski, Philippe, Lebtahi, Rachida, Imperiale, Alessio, and de Mestier, Louis

Published
2023
Full Text
View/download PDF

40. Identification of protease-sensitive but not misfolding PNLIP variants in familial and hereditary pancreatitis

Author

Abrantes, Amandine, Aguilera Munoz, Lina, Albouys, Jérémie, Alric, Laurent, Amiot, Xavier, Archambeaud, Isabelle, Audiau, Solène, Bastide, Laetitia, Baudon, Julien, Bellaiche, Guy, Bellon, Serge, Bertrand, Valérie, Bideau, Karine, Billiemaz, Kareen, Billioud, Claire, Bonnefoy, Sabine, Borderon, Corinne, Bournet, Barbara, Breton, Estelle, Brugel, Mathias, Buscail, Louis, Cadiot, Guillaume, Camus, Marine, Causse, Xavier, Chamouard, Patrick, Chaput, Ulriikka, Cholet, Franck, Ciocan, Dragos Marius, Clavel, Christine, Coffin, Benoit, Coimet-Berger, Laura, Creveaux, Isabelle, Culetto, Adrian, Daboussi, Oussama, Dalstein, Véronique, De Mestier, Louis, Degand, Thibault, d'Engremont, Christelle, Denis, Bernard, Dermine, Solène, Desgrippes, Romain, Drouet d'Aubigny, Augustin, Enaud, Raphaël, Fabre, Alexandre, Gargot, Dany, Gelsi, Eve, Gentilcore, Elena, Gincul, Rodica, Ginglinger-Favre, Emmanuelle, Giovannini, Marc, Gomercic, Cécile, Gondran, Hannah, Grainville, Thomas, Grandval, Philippe, Grasset, Denis, Grimaldi, Stéphane, Grimbert, Sylvie, Hagege, Hervé, Heissat, Sophie, Hentic, Olivia, Herber-Mayne, Anne, Hervouet, Marc, Hoibian, Solene, Jacques, Jérémie, Jais, Bénédicte, Kaassis, Mehdi, Koch, Stéphane, Lacaze, Elodie, Lacroute, Joël, Lamireau, Thierry, Laurent, Lucie, Le Guillou, Xavier, Leblanc, Sarah, Levy, Philippe, Lievre, Astrid, Lorenzo, Diane, Maire, Frédérique, Marcel, Kévin, Matias, Clément, Mauillon, Jacques, Morgant, Stéphanie, Moussata, Driffa, Muller, Nelly, Nambot, Sophie, Napoleon, Bertrand, Olivier, Anne, Pagenault, Maël, Pelletier, Anne-laure, Pennec, Olivier, Pinard, Fabien, Pioche, Mathieu, Prost, Bénédicte, Queneherve, Lucille, Rebours, Vinciane, Reboux, Noemi, Rekik, Samia, Riachi, Ghassan, Rohmer, Barbara, Roquelaure, Bertrand, Rosa Hezode, Isabelle, Rostain, Florian, Saurin, Jean-Christophe, Servais, Laure, Stan-Iuga, Roxana, Subtil, Clément, Texier, Charles, Thomassin, Lucie, Tougeron, David, Tsakiris, Laurent, Valats, Jean-Christophe, Vuitton, Lucine, Wallenhorst, Timothée, Wangerme, Marc, Zanaldi, Hélène, Zerbib, Frank, Masson, Emmanuelle, Berthet, Stéphanie, Le Gac, Gerald, Le Rhun, Marc, Ka, Chandran, Autret, Sandrine, Gourlaouen, Isabelle, Cooper, David N., Férec, Claude, and Chen, Jian-Min

Published
2023
Full Text
View/download PDF

43. Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma

Author

Vienot, Angélique, Beinse, Guillaume, Louvet, Christophe, de Mestier, Louis, Meurisse, Aurélia, Fein, Francine, Heyd, Bruno, Cleau, Denis, d’Engremont, Christelle, Dupont-Gossart, Anne-Claire, Lakkis, Zaher, Tournigand, Christophe, Bouché, Olivier, Rousseau, Benoît, Neuzillet, Cindy, Bonnetain, Franck, Borg, Christophe, and Vernerey, Dewi

Published
2017
Full Text
View/download PDF

46. Spatial and temporal heterogeneity of digestive neuroendocrine neoplasms.

Author

Bourdeleau, Pauline, Couvelard, Anne, Ronot, Maxime, Lebtahi, Rachida, Hentic, Olivia, Ruszniewski, Philippe, Cros, Jérôme, and de Mestier, Louis

Abstract

Neuroendocrine neoplasms (NENs) are initially monoclonal neoplasms that progressively become polyclonal, with very different genotypic and phenotypic characteristics leading to biological differences, including the Ki-67 proliferation index, morphology, or sensitivity to treatments. Whereas inter-patient heterogeneity has been well described, intra-tumor heterogeneity has been little studied. However, NENs present a high degree of heterogeneity, both spatially within the same location or between different lesions, and through time. This can be explained by the emergence of tumor subclones with different behaviors. These subpopulations can be distinguished by the Ki-67 index, but also by the expression of hormonal markers or by differences in the intensity of uptake on metabolic imaging, such as 68Ga-somatostatin receptor and Fluorine-18 fluorodeoxyglucose positron emission tomography. As these features are directly related to prognosis, it seems mandatory to move toward a standardized, improved selection of the tumor areas to be studied to be as predictive as possible. The temporal evolution of NENs frequently leads to changes in tumor grade over time, with impact on prognosis and therapeutic decision-making. However, there is no recommendation regarding systematic biopsy of NEN recurrence or progression, and which lesion to sample. This review aims to summarize the current state of knowledge, the main hypotheses, and the main implications regarding intra-tumor spatial and temporal heterogeneity in digestive NENs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

47. Proposal of early CT morphological criteria for response of liver metastases to systemic treatments in gastroenteropancreatic neuroendocrine tumors: Alternatives to RECIST.

Author

de Mestier, Louis, Resche‐Rigon, Matthieu, Dromain, Clarisse, Lamarca, Angela, La Salvia, Anna, de Baker, Lesley, Fehrenbach, Uli, Pusceddu, Sara, Colao, Annamaria, Borbath, Ivan, de Haas, Robbert, Rinzivillo, Maria, Zerbi, Alessandro, Funicelli, Luigi, de Herder, Wouter W., Selberherr, Andreas, Wagner, Anna Dorothea, Manoharan, Prakash, De Cima, Andrea, and Lybaert, Willem

Subjects
*NEUROENDOCRINE tumors, *MEDICAL ethics, *PROPORTIONAL hazards models, *INTESTINAL tumors, *PROGNOSIS, *TREATMENT effectiveness
Abstract

RECIST 1.1 criteria are commonly used with computed tomography (CT) to evaluate the efficacy of systemic treatments in patients with neuroendocrine tumors (NETs) and liver metastases (LMs), but their relevance is questioned in this setting. We aimed to explore alternative criteria using different numbers of measured LMs and thresholds of size and density variation. We retrospectively studied patients with advanced pancreatic or small intestine NETs with LMs, treated with systemic treatment in the first‐and/or second‐line, without early progression, in 14 European expert centers. We compared time to treatment failure (TTF) between responders and non‐responders according to various criteria defined by 0%, 10%, 20% or 30% decrease in the sum of LM size, and/or by 10%, 15% or 20% decrease in LM density, measured on two, three or five LMs, on baseline (≤1 month before treatment initiation) and first revaluation (≤6 months) contrast‐enhanced CT scans. Multivariable Cox proportional hazard models were performed to adjust the association between response criteria and TTF on prognostic factors. We included 129 systemic treatments (long‐acting somatostatin analogs 41.9%, chemotherapy 26.4%, targeted therapies 31.8%), administered as first‐line (53.5%) or second‐line therapies (46.5%) in 91 patients. A decrease ≥10% in the size of three LMs was the response criterion that best predicted prolonged TTF, with significance at multivariable analysis (HR 1.90; 95% CI: 1.06–3.40; p =.03). Conversely, response defined by RECIST 1.1 did not predict prolonged TTF (p =.91), and neither did criteria based on changes in LM density. A ≥10% decrease in size of three LMs could be a more clinically relevant criterion than the current 30% threshold utilized by RECIST 1.1 for the evaluation of treatment efficacy in patients with advanced NETs. Its implementation in clinical trials is mandatory for prospective validation. Criteria based on changes in LM density were not predictive of treatment efficacy. Clinical Trial Registration: Registered at CNIL‐CERB, Assistance publique hopitaux de Paris as "E‐NETNET‐L‐E‐CT" July 2018. No number was assigned. Approved by the Medical Ethics Review Board of University Medical Center Groningen. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

49. Chemotherapy in advanced pancreatic adenosquamous carcinoma: A retrospective multicenter AGEO study.

Author

Auvray Kuentz, Marie, Hautefeuille, Vincent, de Mestier, Louis, Coutzac, Clélia, Lecomte, Thierry, Nardon, Victor, Artru, Pascal, Turpin, Anthony, Drouillard, Antoine, Malka, David, Tran‐Minh, My‐Linh, Trouilloud, Isabelle, Lièvre, Astrid, Williet, Nicolas, Pernot, Simon, Touchefeu, Yann, Taieb, Julien, Hammel, Pascal, and Zaanan, Aziz

Subjects
CANCER chemotherapy, CARCINOMA, OVERALL survival, PROGRESSION-free survival, PANCREATIC cancer
Abstract

Pancreatic adenosquamous carcinoma (PASC) account for <5% of pancreatic malignancies. The efficacy of modern chemotherapy regimens in patients with advanced PASC is unknown. Patients with advanced PASC from 2008 to 2021 were consecutively included in this retrospective multicenter study. Overall survival (OS) and progression‐free survival (PFS) were evaluated by Kaplan‐Meier method. Ninety‐four PASC from 16 French centers were included (median age, 67.3 years; males, 56.4%; metastatic disease, 85.1%). The first‐line treatment was chemotherapy for 79 patients (84.0%) (37 FOLFIRINOX (FX), 7 Gemcitabine‐nab paclitaxel (GN) and 35 for all other regimen) or best supportive care (BSC) alone for 15 patients (16.0%). No significant difference was observed between FX and GN in terms of PFS (P =.67) or OS (P =.5). Modern regimens pooled together (FX and GN) as compared to all others chemotherapy regimens showed an improvement of overall response rate (39.5% and 9.7%, P =.002), PFS (median, 7.8 vs 4.7 months, P =.02) and OS (median, 12.7 vs 9.2 months, P =.35). This large study evaluating first‐line treatment regimens in advanced PASC suggests that modern regimens as FX or GN may be preferable to all other chemotherapy regimens. These results deserve confirmation in prospective studies. What's new? Pancreatic adenosquamous carcinoma (PASC) is a rare pancreatic cancer subtype of uncertain histological origin. Owing to its scarcity, little is known about the efficacy of chemotherapy for PASC, particularly for advanced disease. Here, investigation of modern chemotherapy regimens in a large multicenter cohort consisting of patients with advanced PASC suggests that more recent regimens based on 5‐fluorouracil, particularly FOLFIRINOX (FX), as well as regimens based on gemcitabine, namely gemcitabine‐nab paclitaxel (GN), are more effective for advanced PASC compared to more conventional regimens. Notably, overall response rates and survival rates were improved in advanced PASC patients on FX and GN regimens. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

50. Carcinoid heart disease in patients with midgut neuroendocrine tumours.

Author

Delhomme, Clémence, Walter, Thomas, Arangalage, Dimitri, Suc, Gaspard, Hentic, Olivia, Cachier, Agnès, Alkhoder, Soleiman, François, Laurent, Lombard‐Bohas, Catherine, Iung, Bernard, Ruszniewski, Philippe, and de Mestier, Louis

Subjects
NEUROENDOCRINE tumors, CARDIAC patients, CARCINOID, RIGHT ventricular dysfunction, TRICUSPID valve insufficiency, PULMONARY valve
Abstract

Carcinoid heart disease (CHD) is the main complication of carcinoid syndrome (CS) associated with metastatic small intestine neuroendocrine tumours (NETs). The pathophysiology of CHD is partly understood but vasoactive hormones secreted by NETs, especially serotonin, play a major role, leading to the formation of fibrous plaques. These plaque‐like deposits involve the right side of the heart in >90% of cases, particularly the tricuspid and pulmonary valves, which become thickened, retracted and immobile, resulting in regurgitation or stenosis. CHD represents a major diagnostic and therapeutic challenge for patients with NET and CS and is associated with increased risk of morbidity and mortality. CHD often occurs 2–5 years after the diagnosis of metastatic NET, but diagnosis of CHD can be delayed as patients are often asymptomatic for a long time despite severe heart valve involvement. Circulating biomarkers (5HIAA, NT‐proBNP) are relevant tools but transthoracic echocardiography is the key examination for diagnosis and follow‐up of CHD. However, there is no consensus on the optimal indications and frequency of TTE and biomarker dosing regarding screening and diagnosis. Treatment of CHD is complex and requires a multidisciplinary approach. It relies on antitumour treatment, control of CS and surgical valve replacement in cases of severe CHD. However, cardiac surgery is associated with a high risk of mortality, notably due to perioperative carcinoid crisis and right ventricular dysfunction. Timing of surgery is the most crucial point of CHD management and relies on the case‐by‐case determination of the optimal compromise between tumour progression, cardiac symptoms and CS control. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results